12082 results for "cancer rna-seq"

in 16.77 milliseconds.

• Reference epigenome Islet-derived-iPSC02 h3k9me3 ChIP-Seq data generated from KEP study

  Islet-derived-iPSC02 h3k9me3 ChIP-Seq paired end data

  Dataset EGAD00001007448

• ALI culture bronchial cells and alveolar lung surgical resection scRNA-Seq

  ALI culture bronchial cells and alveolar lung surgical resection scRNA-Seq

  Dataset EGAD00001006185

• Reference epigenome Islet-derived-MSC01 h3k36me3 ChIP-Seq data generated from KEP study

  Islet-derived-MSC01 h3k36me3 ChIP-Seq paired end data

  Dataset EGAD00001007404

• Reference epigenome Islet-derived-MSC02 h3k4me1 ChIP-Seq data generated from KEP study

  Islet-derived-MSC02 h3k4me1 ChIP-Seq paired end data

  Dataset EGAD00001007412

• Reference epigenome Islet-derived-iPSC02 h3k36me3 ChIP-Seq data generated from KEP study

  Islet-derived-iPSC02 h3k36me3 ChIP-Seq paired end data

  Dataset EGAD00001007445

• Reference epigenome Islet-derived-iPSC02 h3k4me1 ChIP-Seq data generated from KEP study

  Islet-derived-iPSC02 h3k4me1 ChIP-Seq paired end data

  Dataset EGAD00001007446

• HCA_Reproductive_Tract_Adult_RNA

  HCA Reproductive Tract Adult RNA

  Study EGAS00001006636

• Sample Multiplexing Oligo Comparison

  In this study, we compared various multiplexing reagents, including MULTI-Seq, Hashtag antibody, and CellPlex, in patient-derived xenografts (PDXs). We found that all multiplexing reagents worked well in cell types robust to ex vivo manipulation but suffered from signal-to-noise issues in more delicate sample types. We also compared the performance of fixed scRNA-Seq kits and CRISPR-based destruction of non-informative genes.

  Study EGAS50000000153

• Single Cell Dissection of the Tumour Microenvironment Reveals Dynamic Interplay Shaping the Tumour Immunity Continuum in Ovarian Cancer

  Diverse tumour immune phenotypes with distinct T cell infiltration patterns result in different responses to cancer immunotherapies. However, the key determinants and biology underpinning these phenotypes remain elusive. Here, we provide a high-resolution dissection of the tumour microenvironment representative of different tumour immune phenotypes. By performing single-cell RNA sequencing (scRNAseq) of the tumour, immune, and stromal compartments from 15 ovarian cancer patients, we characterized the diverse cellular and functional phenotypes, as well as dynamic interplay within and between these components. Infiltrated and excluded tumours markedly differed from desert tumours in several tumour cell intrinsic features, including high interferon response, antigen presentation and oxidative phosphorylation. Moreover, these tumours were characterized by tumour associated macrophage (TAM)-like myeloid subsets, while desert tumours were enriched in myeloid derived suppressive cell (MDSC)-like myeloid subsets. Infiltrated and excluded tumours differed in their T cell composition and fibroblast subsets. While dysfunctional CD8+ GZMB T cells and IL1-activated fibroblasts (IL1 CAFs) were associated with infiltrated tumours, pre-dysfunctional CD8+ GZMK T cells and TGFB-activated fibroblasts (TGFB CAFs) were enriched in excluded tumours. These findings validated in bulk transcriptomic profiles of 1071 ovarian tumours and using in situ hybridization. Furthermore, our study revealed chemokine receptor-ligand interactions within and across compartments as potential mechanisms mediating immune cell infiltration, exemplified by the tumour cell-T cell crosstalk via a CXC16-CXCR6 axis, stromal-immune cell crosstalk via CXCL12/14-CXCR4 signalling, and TAM-like macrophage-T cell crosstalk through CXCR3-CXCL9/10/11 signalling. Our in-depth characterization of the tumour environment and intercellular interactions provides novel insights into potential molecular mechanisms that shape the distinct biology of tumour immune phenotypes. Our findings may inform novel therapeutic strategies for potentially shifting tumours along the immunity continuum to improve clinical benefit from cancer immunotherapies.

  Study EGAS00001004935

• CATNON: IDH-mutant astroctyoma RNA FASTQ

  Raw fastq files obtained by RNA sequencing 138 IDH-mutant astrocytomas included in the CATNON trial. RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissue blocks using the RNeasy FFPE kit. RNA sequencing was performed on an Illumina NovaSeq 6000 (GenomeScan BV, Leiden, The Netherlands) with 150bp paired-end reads including UMI tags.

  Dataset EGAD50000000558